Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678951 | 0.74 | BTK (0.47) | — | |
| SCHEMBL16588099 | 0.72 | CCR1 (0.48) | TGFBR1THRBCCR1ALDH1A1MAPK1 | |
| SCHEMBL9145225 | 0.70 | CCR1 (0.46) | TGFBR1THRBCCR1ALDH1A1MAPK1 | |
| SCHEMBL20436530 | 0.70 | TGFBR1 (0.37) | TGFBR1THRBCCR1TRPV3 | |
| SCHEMBL9641705 | 0.70 | CCR1 (0.64) | TGFBR1CCR1ALDH1A1 | |
| SCHEMBL20416933 | 0.69 | CYP1A2 (0.42) | ALDH1A1 | |
| SCHEMBL12577773 | 0.68 | HTR7 (0.44) | TGFBR1THRBCCR1ALDH1A1TRPV3 | |
| SCHEMBL486201 | 0.65 | CCR1 (0.55) | CCR1 | |
| SCHEMBL2070847 | 0.65 | NOS1 (0.40) | TGFBR1THRBCCR1ALDH1A1MAPK1 | |
| SCHEMBL13184148 | 0.65 | BCHE (0.39) | TGFBR1THRBCCR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | VIP, PDE3B, ADCY5 | TGFBR1 4617/4885THRB 3116/4885CCR1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.